论文部分内容阅读
病人和方法研究对象为1978年(74例)和1986年(316例)因心脏手术而接受输血的病人,作者对其血清谷丙转氨酶(ALAT)水平和输血后非甲非乙型肝炎的发生作前瞻性研究。对经第一代抗-丙型肝炎病毒抗体(抗-HCV)C100-3酶联免疫吸附法(ELLSA)测定的血清标本,再用第二代试验复查,包括HCV基因的核心(c22)和NS3(c33)区抗原。结果1978年输血后6个月内74例中7例(9%)病人应用抗-HCV C100-3第一代ELISA测定,发现有血清阳转,11例(15%)用
Patients and Methods Patients were enrolled for cardiac surgery in 1978 (n = 74) and in 1986 (n = 316). The authors evaluated their serum levels of alanine aminotransferase (ALAT) and post-transfusion non-A, non-B hepatitis For the prospective study. Serum samples from the first generation of anti-HCV antibodies (anti-HCV) C100-3 ELISA (ELLSA) were retested using a second generation assay including the core of the HCV gene (c22) and NS3 (c33) region antigen. Results Seven of the 74 patients (9%) within 6 months after the transfusion in 1978 were seropositive with anti-HCV C100-3 first-generation ELISA and 11 (15%) with